The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ANCA-Associated Vasculitis in Systemic Sclerosis

ANCA-Associated Vasculitis in Systemic Sclerosis

October 1, 2014 • By Carmen Busca Arenzana, MR, Ander Mayor-Ibarguren, MR, Amara Pieren-Salazar, MR, Natalia Martin-Suñe, MD, Isabel Esteban-Rodríguez, MD, Juan José Ríos-Blanco, MD, & Francisco Arnalich-Fernández, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Muscle & Peripheral Nerve Disease?Muscle & Peripheral Nerve Disease?
Figures: Muscle biopsy (hematoxylin-eosin), which shows striated muscle with necrotizing vasculitis (microscopic polyangiitis) and signs of denervation.

Patients with diffuse systemic sclerosis (dSS) with an associated ANCA-positive vasculitis have been infrequently described. In this article, we report the case of a 53-year-old woman, previously diagnosed with dSS, who developed an ANCA-associated vasculitis, which manifest as peripheral nerve and muscle disease.

You Might Also Like
  • Diagnostic Criteria, Classification Lacking for Vasculitis; New Research in Treatment for Systemic Sclerosis
  • Systemic Sclerosis Mortality Rate May Be Underestimated
  • Dermatology Case: History of ANCA–Associated Vasculitis, Fever, Rash
Explore This Issue
October 2014

Scleroderma is a disease characterized by sclerosis of the skin and visceral organs, vasculopathy, Raynaud’s phenomenon and the presence of autoantibodies. The disease spectrum is wide, with systemic and localized forms, depending on the extent of skin thickening. There is also a vasculopathy involving multiple organ systems that leads to the presence of cutaneous and mucosal telangiectasias, digital ulcers and tissue ischemia. Medium-size vessels can also be involved, sometimes leading to scleroderma renal crisis or pulmonary artery hypertension. However, scleroderma is rarely associated with an ANCA-positive vasculitis. We report this unique situation.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Case Report

A 53-year-old woman was admitted to our hospital with weakness and numbness in her legs. She had been diagnosed with Raynaud’s phenomenon 10 years before, followed by the development of autoimmune hypothyroidism. Three years later, she complained of telangiectasias spreading over her face and neck, and she developed a digital ulcer on her middle finger. She noted a dry cough and dyspnea on exertion. The ANA and the anti-topoisomerase antibodies (Scl-70) were positive. She was diagnosed with dSS with pulmonary involvement (moderate to severe pulmonary fibrosis).

There was no evidence for pulmonary hypertension, or cardiac or esophageal involvement. After being treated for a presumed episode of pneumonia, she failed to significantly improve, and her cough and dyspnea worsened. She complained of weakness and numbness in her distal lower extremities with preserved muscle strength and hypoesthesia to touch.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The development of vasculitis in patients with systemic sclerosis is highly uncommon.

Initial laboratory tests included a normocytic and normochromic anemia, thrombocytosis, elevated acute-phase reactants and normal serum creatinine. MPO-ANCA titer was 174 AU (normal <10 UI/mL). PR-3-ANCA was negative. Antiglomerular basal membrane and anti-Jo-1 antibodies were negative, and complement C3 and C4 were within normal limits. An electromyogram showed evidence of a moderate myopathy without polyneuropathy or myositis. A muscle and peripheral nerve biopsy demonstrated features of a necrotizing vasculitis with signs of axonal degeneration and severe denervation attributable to ischemic neuropathy (see figures, right).

Therapy was initiated with a high dose of prednisolone (bolus of 1 mg/kg/day IV for three days, followed by 60 mg PO daily) and cyclophosphamide treatment (five monthly IV boluses of 750 mg each) was initiated. A few weeks later, maintenance immunosuppressive therapy was introduced with azathioprine (150 mg day PO), and her hypoesthesia and weakness gradually disappeared.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Scleroderma Tagged With: ANCA vasculitis, drug, patient care, peripheral nerve disease, prednisone, Raynaud's, rheumatologist, Scleroderma, Systemic sclerosis, Treatment, VasculitisIssue: October 2014

You Might Also Like:
  • Diagnostic Criteria, Classification Lacking for Vasculitis; New Research in Treatment for Systemic Sclerosis
  • Systemic Sclerosis Mortality Rate May Be Underestimated
  • Dermatology Case: History of ANCA–Associated Vasculitis, Fever, Rash
  • Fellow’s Forum Case Report: Limited Cutaneous Systemic Sclerosis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)